StrideBio Revenue and Competitors

Location

$97.2M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • StrideBio's estimated annual revenue is currently $1.6M per year.(i)
  • StrideBio's estimated revenue per employee is $77,500
  • StrideBio's total funding is $97.2M.

Employee Data

  • StrideBio has 21 Employees.(i)
  • StrideBio grew their employee count by -82% last year.

StrideBio's People

NameTitleEmail/Phone
1
VP Strategy & OperationsReveal Email/Phone
2
EVP Finance and AdministrationReveal Email/Phone
3
VP Strategy & OperationsReveal Email/Phone
4
VP, Head Finance and Corporate SecretaryReveal Email/Phone
5
VP Regulatory AffairsReveal Email/Phone
6
VP Patient Engagement & AdvocacyReveal Email/Phone
7
VP Human ResourcesReveal Email/Phone
8
VP Strategy & OperationsReveal Email/Phone
9
Chief Development OfficerReveal Email/Phone
10
Founder, Acting Chief Scientific OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.2M72-13%N/AN/A
#2
$5099.8M32902-4%N/AN/A
#3
$1.7M110%N/AN/A
#4
$0.6M4-56%N/AN/A
#5
$0.9M11-39%N/AN/A
#6
$1.7M1110%N/AN/A
#7
$0.6M4-33%N/AN/A
#8
$4.8M31-6%N/AN/A
#9
$6.4M413%N/AN/A
#10
$4.2M27-18%N/AN/A
Add Company

What Is StrideBio?

StrideBio is a product-driven, fully integrated gene therapy company focused on creating and developing innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond. We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBioᅢᄁ¬ツᆲ¬トᄁs AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency. StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C, which houses our offices, research labs and in-house AAV manufacturing facilities.

keywords:N/A

$97.2M

Total Funding

21

Number of Employees

$1.6M

Revenue (est)

-82%

Employee Growth %

N/A

Valuation

N/A

Accelerator

StrideBio News

2021-03-16 - StrideBio Closes $81.5M Series B Financing

StrideBio, Inc., a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies, closed a $81.5m Series B funding round. The round was co-led by Northpond Ventures and Novo Holdings A/S and included new investors Pontifax, Octagon Capital, S ...

2021-03-16 - StrideBio Announces Closing of $81.5M Series B Financing

RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. The financing was co-led ...

2021-03-16 - StrideBio Announces Closing of $81.5M Series B Financing

RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. The financing was co-led b ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.3M21-28%N/A
#2
N/A210%N/A
#3
$3.3M2117%N/A
#4
$3.4M210%N/A
#5
$4M21-25%N/A